Study of ODX (OsteoDex) in Multiple Myeloma

Trial Title: Study of ODX (OsteoDex) in Multiple Myeloma

NCT ID: NCT06616389

Condition: Multiple Myeloma

Conditions: Official terms:
Multiple Myeloma
Neoplasms, Plasma Cell

Study type: Interventional

Study phase: Phase 1/Phase 2

Overall status: Recruiting

Study design:

Allocation: N/A

Intervention model: Single Group Assignment

Intervention model description: Ascending dose study to evaluate safety and biological efficacy of up to 3 dose levels of ODX

Primary purpose: Treatment

Masking: None (Open Label)

Intervention:

Intervention type: Drug
Intervention name: ODX (Osteodex)
Description: Multi-center, prospective, open-label, ascending dose study to evaluate safety and biological efficacy of up to 3 dose levels of ODX.
Arm group label: Ascending dose

Summary: The current phase I/IIa trial is a multi-center, prospective, open-label, ascending dose study to evaluate safety and biological efficacy of up to 3 dose levels of ODX. Each dose cohort will consist of 4 subjects. Each subject will receive up to 7 doses of ODX, given at 2-week intervals, until unacceptable toxicity or disease progression. A follow-up visit will be conducted 2 weeks after the last dose. Primary objectives: • To determine the safety and tolerability of ODX in subjects with relapsed/refractory multiple myeloma. Secondary objectives: - To evaluate the preliminary efficacy of ODX, as determined by the IMWG response criteria, in subjects with relapsed/refractory multiple myeloma. - To evaluate the efficacy of ODX on serum biomarkers (M-protein, FLC, CTX, osteocalcin, and bone-specific S-ALP) in subjects with relapsed/refractory multiple myeloma. Exploratory objective • To evaluate time to progression by following M-protein and FLC levels as per clinical routine

Criteria for eligibility:
Criteria:
Inclusion Criteria: - 1. Subject (male or female) is ≥ 18 years of age at the time of signing the informed consent form (ICF). 2. Documented diagnosis av multiple myeloma according to the International Myeloma Working Group (IMWG) diagnostic criteria. 3. Measurable disease defined as either: - Serum monoclonal paraprotein (M-protein) level ≥ 0.5 g/dL or urine M-protein level ≥ 200 mg/24 hours; or - Light chain multiple myeloma without measurable disease in the serum or the urine: Serum immunoglobulin free light chain (FLC) ≥ 10 mg/dL and abnormal serum immunoglobulin kappa lambda FLC ratio. 4. Subjects must have received 1-5 prior lines of therapy including a PI, IMiD and CD38 antibody*. *Patients eligible for inclusion should have received said treatments, i.e., according to clinical routine, unless contraindicated due to induced morbidity. 5. Subjects must have documented evidence of progressive disease based on the IMWG criteria on or after their last line of therapy. 6. Performance status ECOG 0-2 7. Laboratory requirements: Haematology: Neutrophils ≥ 1.0 x 109/l Hemoglobin ≥ 80 g/l Platelets ≥ 50 x 109/l Hepatic function: Total S/P-bilirubin ≤ 1.5 times the upper limit of normal (ULN) AST (SGOT) / ALT (SGPT) ≤ 2.5 times ULN Renal function: S/P-creatinine ≤ 1.5 times ULN Electrolytes: S/P-sodium, S/P-potassium, S/P-calcium corrected for S/P albumin , S/P-phosphate, and S/P magnesium, all within normal ranges. At the discretion of the Investigator, supplements may be given to correct these values, in which case electrolytes must be shown to be within normal ranges before inclusion into the study. 8. No evidence (< 5 years) of prior malignancies (except successfully treated basal cell or squamous cell carcinoma of the skin). 9. Able to adhere to the study visit schedule and other protocol requirements. Exclusion Criteria: 1. Concurrent use of other anti-cancer agents/treatments. 2. Any treatment modalities involving chemotherapy, radiation, or major surgery within 4 weeks prior to treatment in this study. 3. Simultaneous participation in any other study involving investigational drugs or having participated in an investigational study less than 4 weeks prior to start of study treatment. 4. Any condition, including the presence of laboratory abnormalities, which confounds the ability to interpret data from the study or places the patient at unacceptable risk if he or she participates in the study. 5. Known active CNS involvement or exhibits clinical signs of meningeal involvement of multiple myeloma. 6. Plasma cell leukemia, Waldenstrom's macroglobulinemia or POEMS syndrome. 7. Dental surgery (dental extraction), periodontal disease, local trauma including poorly fitting dentures within 6 months prior to the first dose of study drug. 8. Treatment with bisphosphonates or denosumab within 6 weeks prior to first dose of study medication. 9. Male subjects not willing to use condom to prevent pregnancy and drug exposure of a fertile female partner and refrain from donating sperm from the date of the first dose until the end of study treatment. 10. Pregnant or breastfeeding females. 11. Female subjects of childbearing potential** not willing to use a contraceptive method with a failure rate of < 1% to prevent pregnancy during study treatment. Highly effective birth control methods include: - combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation: - oral - intravaginal - transdermal - progestogen-only hormonal contraception associated with inhibition of ovulation: - oral - injectable - implantable - intrauterine device - intrauterine hormone-releasing system (for example, progestin-releasing coil) - vasectomized male (with appropriate post vasectomy documentation of the absence of sperm in the ejaculate) - bilateral tubal occlusion or hysterectomy. **Female subjects are considered of non-childbearing potential if they are pre-menopausal females with a documented tubal ligation or hysterectomy or bilateral oophorectomy; or as post-menopausal females defined as at least 12 months of amenorrhea. 12. Subjects in which pre-medication with dexamethasone, antihistamine, and paracetamol would be contraindicated.

Gender: All

Minimum age: 18 Years

Maximum age: N/A

Healthy volunteers: No

Locations:

Facility:
Name: Karolinska Universitetssjukhuset Huddinge Cancerstudieenheten M62

Address:
City: Stockholm
Zip: 14186
Country: Sweden

Status: Recruiting

Contact:
Last name: Katarina Uttervall, MD, PhD

Phone: +46 724694954
Email: katarina.uttervall@regionstockholm.se

Investigator:
Last name: Katarina Uttervall
Email: Principal Investigator

Facility:
Name: Uddevalla Sjukhus, Hematologens dagvård

Address:
City: Uddevalla
Zip: 45180
Country: Sweden

Status: Recruiting

Contact:
Last name: Dorota Knut, MD

Phone: +46 10 4354701
Email: Dorota.knut@vgregion.se

Investigator:
Last name: Dorota Knut
Email: Principal Investigator

Start date: September 5, 2023

Completion date: June 30, 2025

Lead sponsor:
Agency: DexTech Medical AB
Agency class: Industry

Source: DexTech Medical AB

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT06616389